The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The Antivirals Market By The End Of 2030?
The antivirals market size has seen substantial growth in recent years. It is forecast to increase from $114.4 billion in 2025 to $122.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.7%. Historically, this expansion is attributable to global viral outbreaks, the burden of HIV and hepatitis, government initiatives for antiviral stockpiling, the widespread availability of generics, and the broadening of infectious disease programs.
The antivirals market is projected to experience substantial expansion in the coming years. This market is set to reach a value of $163.33 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.5%. This anticipated growth during the forecast period is primarily driven by factors such as new viral threats, increased investment in antiviral research and development, better integration of vaccination and treatment strategies, various global health initiatives, and the rising need for rapid-response therapeutic solutions. Key trends anticipated in the same period involve a heightened demand for broad-spectrum antiviral agents, an increasing emphasis on preparing for pandemics, the proliferation of generic antiviral medications, greater application in the management of chronic viral infections, and the innovation of antivirals with new mechanisms of action.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2437&type=smp
What Drivers Are Shaping The Future Growth Of The Antivirals Market?
The escalating occurrence of influenza is predicted to boost the expansion of the antiviral market moving forward. Influenza, commonly referred to as flu, is a highly transmissible viral respiratory infection, caused by influenza viruses that impact the nose, throat, and lungs. The rising prevalence of influenza stems primarily from colder conditions and indoor crowding, factors that prolong the virus’s survival and facilitate person-to-person transmission in close quarters. Antivirals are utilized for treating influenza, designed to impede the replication and dissemination of influenza viruses within the body. As an illustration, in November 2024, information from the Centers for Disease Control and Prevention, a US-based national public health agency, showed that the 2023 to 2024 influenza season was estimated to be linked to 40 million illnesses, 18 million medical visits, 470,000 hospitalizations, and 28,000 deaths. Hence, the increasing incidence of influenza is propelling the growth of the antiviral market.
Which Segment Classifications Shape The Antivirals Market?
The antivirals market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes
3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications
Subsegments:
1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)
2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals
How Are Trends Impacting The Antivirals Market?
Leading companies in the antiviral market are prioritizing the development of innovative treatments, such as oral antiviral therapies, to enhance patient adherence, improve accessibility, reduce healthcare expenditures, and offer more convenient and effective options for managing viral infections. Oral antiviral treatment refers to medicines taken by mouth to combat viral infections. These therapies function by inhibiting viruses from replicating or spreading within the body, thereby helping to diminish the severity and duration of the infection. For example, in May 2023, Pfizer, a US-based pharmaceutical company, announced that Paxlovid received approval from the Food and Drug Administration, a US-based government agency, making it the first oral antiviral treatment for COVID-19 in adults. This approval is particularly significant as it introduces a new therapeutic choice for managing COVID-19, especially as the pandemic evolves into an endemic phase. Paxlovid is specifically indicated for adults with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease, including hospitalization or death.
Major companies operating in the antiviral market are focusing on creating advanced therapeutic solutions, including various antiviral treatments, to improve patient outcomes and decrease viral transmission. Antiviral treatments are crucial for controlling viral infections and preventing complications in affected individuals. For instance, in August 2024, Red Queen’s Technology, a US-based pharmaceutical company, launched versatile antivirals. Apple Tree Partners has invested $55 million in Red Queen Therapeutics, a biotech firm dedicated to developing broad-spectrum antiviral treatments. The company targets infectious pathogens such as COVID-19 and influenza, having already advanced a COVID antiviral through Phase 1 testing and secured U.S. government funding for a pan-influenza drug. Co-founded by Harvard professor Loren Walensky, Red Queen employs stapled lipopeptides to inhibit viral fusion and block viral entry into cells.
Which Companies Are Expanding Their Footprint In The Antivirals Market?
Major companies operating in the antivirals market are AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Inovio Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., AVI Biopharma International Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.
Read the full antivirals market report here:
https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report
Which Geographic Regions Are Influencing Demand In The Antivirals Market?
North America was the largest region in the anti-viral drug therapy market in 2025. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Antivirals Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=2437&type=smp
Browse Through More Reports Similar to the Global Antivirals Market 2026, By The Business Research Company
Antivirals Market Report 2026
https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report
Antiviral Combination Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report
Anti Infective Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model